Clinical trial NCT04277156: L Rhamnosus ATCC 53103 & L Reuteri DSM 29063 Compared With L Rhamnosus ATCC 53103 for Preventing AAD in Children
Official title: A Two-strain Probiotic (L Rhamnosus ATCC 53103 & L Reuteri DSM 29063) Compared With a Single Strain Probiotic (L Rhamnosus ATCC 53103) for Preventing Antibiotic-associated Diarrhea: an Open-label, Randomized, Noninferiority Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Antibiotic-associated Diarrhea
Lead sponsor: Medical University of Warsaw
Sponsor class: OTHER
Collaborators: name: Adamed Pharma S.A.
First posted: 2020-02-20
Enrollment: 892
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will use a noninferiority design to examine whether the administration of L rhamnosus ATCC 53103 \&amp;amp;amp;amp;amp;amp;amp;amp;amp; L reuteri DSM 29063 (Flostrum Baby) is no worse than (or as good as) the administration of a recommended probiotic L rhamnosus ATCC 53103 (commercially available as Dicoflor, hereafter a reference product) for the prevention of antibiotic-associated diarrhea in children,

Detailed description: The recruitment will take place in hospitalized patients at the Pediatric Department of St. Hedwig of Silesia Hospital, Trzebnica, Poland. Additionally, patients treated at the out-patient clinics collaborating with the St. Hedwig of Silesia Hospital will be recruited. The involvement of other recruiting wards and/or sites are under consideration provided that the personnel are adequately trained and competent in conducting clinical trials. The start of the recruitment is planned in March 2020 and should be completed within the following 2 years.

The test product will be Flostrum Baby, which is a food supplement consisting of two bacterial strains: Lactobacillus rhamnosus ATCC 53103 and Lactobacillus reuteri DSM 29063, 5x10\^9 CFU and 1x10\^8 CFU, respectively, per seven drops.

The control product will be Dicoflor, which is a food supplement containing L rhamnosus ATCC 53103, 5x10\^9 CFU, per five drops.

Caregivers will receive oral and written information regarding the study. Written informed consent will be obtained by the physicians involved in the study. Participants will be randomized within 24 hours after the initiation of the antibiotic administration.

Throughout the study period, healthcare providers and/or caregivers will record the number and consistency of stools in a standard stool diary. To record stool consistency, in children younger than 1 year, the Amsterdam Infant Stool Scale (AISS)9 will be used, and loose or watery stools will correspond to A-consistency. In children older than 1 year, the Bristol Stool Form (BSF) scale10 will be used, and loose or watery stools will correspond to scores of 5- 7. In the case of missing or incomplete data, data from hospital charts will be obtained. At any time, caregivers will have the right to withdraw the participating child from the study; they will be not obliged to give reasons for this decision, and there will be no effect on subsequent physician and/or institutional medical care.

In the event of loose or watery stools, the presence of viral or bacterial pathogens in the stool samples will be investigated. The presence of viral pathogens will be checked by using a standard rapid, qualitative, chromatographic immunoassay that simultaneously detects rotaviruses, adenoviruses, and noroviruses. Standard microbiological techniques will be used to isolate and identify bacterial pathogens (Salmonella spp, Shigella spp, Campylobacter spp, and Yersinia spp). C. difficile toxins A and B will be identified by standard enzyme immunoassay.

All study participants will be followed up for the duration of the intervention (antibiotic treatment) and then for up to 1 week after the intervention.

Eligibility criteria: Inclusion criteria:

1. age younger than 18 years;
2. oral or intravenous antibiotic therapy which started within 24 hours of enrolment;
3. signed informed consent.

Exclusion criteria:

1. pre-existing acute or chronic diarrhea, history of chronic gastrointestinal disease (e.g. inflammatory bowel disease, cystic fibrosis, coeliac disease, food allergy) or other severe chronic diseases (eg, neoplastic diseases),
2. major medical problems (eg. immunocompromised, major developmental or genetic abnormality);
3. taking any of the study products (or probiotic strains included in the study products) at the time of study commencement;
4. use of antibiotics within 4 weeks prior to enrolment,
5. prematurity;
6. exclusive breastfeeding.

Primary outcomes:
measure: Antibiotic-associated diarrhea (3 or more loose or watery stools (a score of A on the AIS Scale or 5-7 on the BSF scale) per day in a 24-hour period, caused by C. difficile infection or of otherwise unexpla
timeFrame: From the date of randomisation up to 7th day after antibiotic cessation
Secondary outcomes:
measure: • Any diarrhea (defined as ≥ 3 loose or watery stools per day for a minimum of 24 hours regardless of its etiology).
timeFrame: From the date of randomisation up to 7th day after antibiotic cessation
measure: • C difficile-associated diarrhea (CDAD) (diarrhea defined as above caused by C. difficile confirmed by the presence of toxin-producing C. difficile in stools (positive toxin tests))
timeFrame: From the date of randomisation up to 7th day after antibiotic cessation
measure: • The duration of diarrhea (defined as the time until the normalization of stool consistency according to the BSF or AISS scale (on BSF scale, numbers 1, 2, 3 and 4; on AISS scale, letters B or C), and the presence of normal stools for 48 hours).
timeFrame: From the date of randomisation up to 7th day after antibiotic cessation
measure: • Discontinuation of the antibiotic treatment due to severity of diarrhea.
timeFrame: From the date of randomisation up to 7th day after antibiotic cessation
measure: • Hospitalization caused by diarrhea in outpatient
timeFrame: From the date of randomisation up to 7th day after antibiotic cessation
measure: • Adverse events.
timeFrame: From the date of randomisation up to 7th day after antibiotic cessation
measure: Number and consistency of stools
timeFrame: From the date of randomisation up to 7th day after antibiotic cessation
Other outcomes:
Locations:
city: Trzebnica
country: Poland
facility: Department of Paediatrics, St. Hedwig of Silesia Hospital
Study officials:
affiliation: The Medical Univ of Warsaw, Dept of Paediatrics
name: Hanna Szajewska, MD
role: STUDY_CHAIR
affiliation: Pediatric Department of St. Hedwig of Silesia Hospital
name: Henryk Szymański, MD
role: PRINCIPAL_INVESTIGATOR
References: